[1] Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990—2017:a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet,2019,394(10204):1145-1158.
[2] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2024,74(3):229-263.
[3] 中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版)[J]. 肿瘤综合治疗电子杂志,2024,10(3):17-68.
[4] Feng F, Zhao Y. Hepatocellular carcinoma:prevention, diagnosis, and treatment[J]. Med Princ Pract,2024,33(5):414-423.
[5] Kirstein M M, Wirth T C. Multimodal treatment of hepatocellular carcinoma[J]. Internist (Berl),2020,61(2):164-169.
[6] 安澜, 曾红梅, 郑荣寿, 等. 2015年中国肝癌流行情况分析[J]. 中华肿瘤杂志,2019,41(10):721-727.
[7] Xiao J, Wang F, Wong N K, et al. Epidemiological realities of alcoholic liver disease:global burden, research trends, and therapeutic promise[J]. Gene Expr,2020,20(2):105-118.
[8] Zhu Q, Ma Y, Liang J, et al. AHR mediates the aflatoxin B1 toxicity associated with hepatocellular carcinoma[J]. Signal Transduct Target Ther,2021,6(1):299.
[9] 韩颜泽, 孙惠昕, 徐东升. 1990—2021年中国肝癌流行病学趋势分析[J]. 中华肝脏病杂志,2025,33(2):143-150.
[10] 曹广文. 我国原发性肝癌的流行病学特征及精准防控[J]. 广西医科大学学报,2024,41(11):1455-1463.
[11] 朱逸晨, 沙春霞, 樊春笋, 等. 慢性乙型肝炎患者发生肝癌的危险因素分析及列线图预测模型构建[J]. 临床肝胆病杂志,2024,40(12):2441-2449.
[12] 林钧, 李泽鹏, 余君莹. 有效白蛋白在慢性肝病中的作用[J]. 基础医学与临床,2024,44(12):1707-1711.
[13] 赵润根, 井贺楠, 张越亚. AST/PLT比值指数与乙肝肝硬化抗病毒治疗患者肝癌发生的关系[J]. 实用癌症杂志,2024,39(12):1646-1649.
[14] 张萌, 党至纯, 李婷, 等. 肝硬化合并与不合并原发性肝癌患者血小板数目及凝血功能差异比较研究[J]. 实用肝脏病杂志,2025,28(4):577-580.
[15] Dudiki T, Veleeparambil M, Zhevlakova I, et al. Mechanism of tumor-platelet communications in cancer[J]. Circ Res,2023,132(11):1447-1461.
[16] 宋红亮, 王建国, 张会, 等. 血清学标志物甲胎蛋白、PIVKA-Ⅱ和磷脂酰肌醇蛋白聚糖3联合诊断肝癌的meta分析[J]. 浙江大学学报(医学版),2024,53(11):131-139.
[17] Hann H W, Fu X, Myers R E, et al. Predictive value of alpha-fetoprotein in the long-term risk of developing hepatocellular carcinoma in patients with hepatitis B virus infection-results from a clinic-based longitudinal cohort[J]. Eur J Cancer,2012;48(15):2319-2327.
[18] 黄晨军, 肖潇, 周琳, 等. 肝癌三项(AFP、AFP-L3%、DCP)与GALAD、类GALAD模型临床应用专家共识[J]. 检验医学,2023,38(7):607-623.
[19] 邓霖霖, 石清兰, 韦华柱, 等. 乙型肝炎病毒相关肝细胞癌高危因素分析[J]. 肝脏,2023,28(5):614-617.
[20] Kim G A, Lim Y S, Han S, et al. Viral load-based prediction of hepatocellular carcinoma risk in noncirrhotic patients with chronic hepatitis B :a multinational study for the development and external validation of a new prognostic model[J]. Ann Intern Med,2024,177(10):1308-1318.
[21] Fan R, Papatheodoridis G, Sun J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis[J]. J Hepatol,2020,73(6):1368-1378.
[22] Chen Y, Shi Y, Lu L, et al. The aMAP score is an independent risk factor for intermediate-stage hepatocellular carcinoma:a large retrospective cohort study[J]. J Cancer,2023,14(8):1272-1281.
[23] Yang Y, Zhou Y, Zhang X, et al. Using the aMAP risk score to predict late recurrence following radiofrequency ablation for hepatocellular carcinoma in chinese population:a multicenter study[J]. J Hepatocell Carcinoma,2021,8:837-850.
[24] Elgenidy A, Abubasheer T M, Odat R M, et al. Assessing the predictive accuracy of the amap risk score for hepatocellular carcinoma (HCC):diagnostic test accuracy and meta-analysis[J]. J Clin Exp Hepatol,2025,15(1):102381.
[25] Chen Y, Shi Y, Lu L, et al. The aMAP score is an independent risk factor for intermediate-stage hepatocellular carcinoma:a large retrospective cohort study[J]. J Cancer,2023,14(8):1272-1281.
[26] He H, Wu Y, Jia Z, et al. Risk-stratified approach by aMAP score for community population infected with hepatitis B and C to guide subsequent liver cancer screening practice:a cohort study with 10-year follow-up[J]. J Viral Hepat,2023,30(11):859-869.
[27] Fan R, Chen L, Zhao S, et al. Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures[J]. J Hepatol,2023,79(4):933-944.
[28] Li H, Liu H, Yan L J, et al. Performance of GALAD score and serum biomarkers for detecting NAFLD-related HCC:a systematic review and network meta-analysis[J]. Expert Rev Gastroenterol Hepatol,2023,17(11):1159-1167.
[29] Guan M C, Zhang S Y, Ding Q, et al. The performance of GALAD score for diagnosing hepatocellular carcinoma in patients with chronic liver diseases:a systematic review and meta-analysis[J]. J Clin Med,2023,12(3):949.
[30] Villa E, Donghia R, Baldaccini V, et al. GALAD outperforms aMAP and ALBI for predicting HCC in patients with compensated advanced chronic liver disease:a 12-year prospective study[J]. Hepatol Commun,2023,7(10):e0262.
[31] Yang H I, Yuen M F, Chan H L, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B):development and validation of a predictive score[J]. Lancet Oncol,2011,12(6):568-574.
[32] Sharma S, Acarsu U, Hirschfield G, et al. 111 development of a scoring system to predict risk of hepatocellular carcinoma in a cohort of patients with cirrhosis[J]. J Hepatol,2013,58(S1):S49-S49.
[33] Rizzo G E M, Cabibbo G, Craxì A. Hepatitis B virus-associated hepatocellular carcinoma[J]. Viruses,2022,14(5):986.
[34] Kim S U, Seo Y S, Lee H A, et al. Validation of the CAMD score in patients with chronic hepatitis B virus infection receiving antiviral therapy[J]. Clin Gastroenterol Hepatol,2020,18(3):693-699.
[35] Wang S, Liu B, Fan X, et al. Predicting the risk of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy:validating the CAMD and AASL scores in China[J]. Saudi J Gastroenterol,2022,28(5):362-368.
[36] 黄培宁, 程吉云, 余贤恩, 等. 肝硬化后肝癌患者的临床特征及肝硬化进展为肝癌的危险因素[J]. 广西医学,2020,42(12):1494-1497.
[37] Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy[J]. J Hepatol,2016,64(4):800-806.
[38] Pastras P, Zazas E, Kalafateli M, et al. Predictive risk factors and scoring systems associated with the development of hepatocellular carcinoma in chronic hepatitis B[J]. Cancers (Basel),2024,16(14):2521.
[39] Kim J H, Kim Y D, Lee M, et al. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy[J]. J Hepatol,2018,69(5):1066-1073.
[40] Yang H I, Yeh M L, Wong G L, et al. Real-world effectiveness from the asia pacific rim liver consortium for HBV risk score for the prediction of hepatocellular carcinoma in chronic hepatitis b patients treated with oral antiviral therapy[J]. J Infect Dis,2020,221(3):389-399.
[41] 中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 中华肝脏病杂志,2024,32(5):418-434.
[42] Younossi Z M, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes:a systematic review and meta-analysis[J]. J Hepatol,2019,71(4):793-801.
[43] Pang Y, Kartsonaki C, Turnbull I, et al. Diabetes, plasma glucose, and incidence of fatty liver, cirrhosis, and liver cancer:a prospective study of 0.5 million people[J]. Hepatology,2018,68(4):1308-1318.
[44] Wu S, Zeng N, Sun F, et al. Hepatocellular carcinoma prediction models in chronic hepatitis B:a systematic review of 14 models and external validation[J]. Clin Gastroenterol Hepatol,2021,19(12):2499-2513. |
